Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/23/7243 |
| _version_ | 1797399951451357184 |
|---|---|
| author | Agustín Sancho-Saldaña Anna Gil-Sánchez Cristina González-Mingot Silvia Peralta Maria Jose Solana Pascual Torres Alba Juanes Laura Quibus Emilio Ruiz Eduardo Sanpedro Bibiana Quirant-Sánchez Eva Martínez-Cáceres Cristina Ramo Tello Silvia Presas-Rodríguez Sebatián García Rubio Beatriz Pardiñas Baron Lluís Ramió-Torrentà Javier Sotoca Inés González-Suárez Sara Eichau José M. Prieto-González Maria Rosario Blasco Quilez Julia Sabín-Muñoz Antonio José Sánchez-López Gloria Llorens Calatayud Carmen Calles Ángel Pérez Sempere Moises Garcés Olga Carmona Ester Moral José Vicente Hervás Yolanda Blanco Nuria Sola-Valls Nieves Tellez Lara Lucía Forero Luis Brieva |
| author_facet | Agustín Sancho-Saldaña Anna Gil-Sánchez Cristina González-Mingot Silvia Peralta Maria Jose Solana Pascual Torres Alba Juanes Laura Quibus Emilio Ruiz Eduardo Sanpedro Bibiana Quirant-Sánchez Eva Martínez-Cáceres Cristina Ramo Tello Silvia Presas-Rodríguez Sebatián García Rubio Beatriz Pardiñas Baron Lluís Ramió-Torrentà Javier Sotoca Inés González-Suárez Sara Eichau José M. Prieto-González Maria Rosario Blasco Quilez Julia Sabín-Muñoz Antonio José Sánchez-López Gloria Llorens Calatayud Carmen Calles Ángel Pérez Sempere Moises Garcés Olga Carmona Ester Moral José Vicente Hervás Yolanda Blanco Nuria Sola-Valls Nieves Tellez Lara Lucía Forero Luis Brieva |
| author_sort | Agustín Sancho-Saldaña |
| collection | DOAJ |
| description | Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; <i>p</i> 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population. |
| first_indexed | 2024-03-09T01:48:33Z |
| format | Article |
| id | doaj.art-113662d141fb4a9699c0808fe945e6ff |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T01:48:33Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-113662d141fb4a9699c0808fe945e6ff2023-12-08T15:18:50ZengMDPI AGJournal of Clinical Medicine2077-03832023-11-011223724310.3390/jcm12237243Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre StudyAgustín Sancho-Saldaña0Anna Gil-Sánchez1Cristina González-Mingot2Silvia Peralta3Maria Jose Solana4Pascual Torres5Alba Juanes6Laura Quibus7Emilio Ruiz8Eduardo Sanpedro9Bibiana Quirant-Sánchez10Eva Martínez-Cáceres11Cristina Ramo Tello12Silvia Presas-Rodríguez13Sebatián García Rubio14Beatriz Pardiñas Baron15Lluís Ramió-Torrentà16Javier Sotoca17Inés González-Suárez18Sara Eichau19José M. Prieto-González20Maria Rosario Blasco Quilez21Julia Sabín-Muñoz22Antonio José Sánchez-López23Gloria Llorens Calatayud24Carmen Calles25Ángel Pérez Sempere26Moises Garcés27Olga Carmona28Ester Moral29José Vicente Hervás30Yolanda Blanco31Nuria Sola-Valls32Nieves Tellez Lara33Lucía Forero34Luis Brieva35Neurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeuroimmunology Group, Department of Medicine, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainMultiple Sclerosis Foundation from Lleida, 25198 Lleida, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeuroimmunology Group, Department of Medicine, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeuroimmunology Group, Department of Medicine, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainImmunology Division, Hospital Germans Trias i Pujol, LCMN, 08916 Badalona, SpainImmunology Division, Hospital Germans Trias i Pujol, LCMN, 08916 Badalona, SpainMultiple Sclerosis and Clinical Neuroimmunology Unit, Neurosciences Department, Hospital Germans Trias i Pujol, 08916 Badalona, SpainMultiple Sclerosis and Clinical Neuroimmunology Unit, Neurosciences Department, Hospital Germans Trias i Pujol, 08916 Badalona, SpainNeurology Department, Hospital Universitario Miguel Servet, 50009 Zaragoza, SpainNeurology Department, Hospital Universitario Miguel Servet, 50009 Zaragoza, SpainGirona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital, 17007 Girona, SpainNeurology Department, Hospital Universitari MutuaTerrassa, 08035 Barcelona, SpainDepartment of Neurology, Complejo Hospitalario Universitario de Vigo, Calle Clara Campoamor, 341, 36213 Vigo, SpainMultiple Sclerosis Unit, Hospital Universitario Virgen Macarena, 41009 Seville, SpainFundación Instituto de Investigación Sanitaria de Santiago (IDIS), 15706 Santiago de Compostela, SpainNeuroimmunology Unit, Clínica Puerta de Hierro, Universidad Autónoma de Madrid, 28222 Madrid, SpainNeuroimmunology Unit, Clínica Puerta de Hierro, Universidad Autónoma de Madrid, 28222 Madrid, SpainBiobank, Puerta de Hierro-Segovia de Arana Health Research Institute, 28222 Madrid, SpainDepartment of Neurology, Hospital Mateu Orfila, 07703 Mahón, SpainDepartment of Neurology, Hospital Universitari Son Espases, 07120 Palma de Mallorca, SpainDepartment of Neurology, Hospital General Universitario Dr. Balmis de Alicante, Universidad Miguel Hernández de Elche, 03202 Elche, SpainDepartment of Neurology, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, SpainDepartment of Neurology, Fundació Salut Empordà, 17600 Girona, SpainHospital de Sant Joan Despí Moisès Broggi, 08970 Sant Joan Despí, SpainHospital de Sant Joan Despí Moisès Broggi, 08970 Sant Joan Despí, SpainNeuroimmunology and Multiple Sclerosis Unit, Neurology Service, Hospital Clinic de Barcelona, 08036 Barcelona, SpainDepartment of Neurology, Hospital Universitari Sant Joan de Reus, 43204 Tarragona, SpainDepartment of Neurology, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, SpainDepartment of Neurology, Hospital Puerta del Mar, 11009 Cádiz, SpainNeurology Department, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida-IRBLleida, 25198 Lleida, SpainBackground: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; <i>p</i> 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population.https://www.mdpi.com/2077-0383/12/23/7243Multiple SclerosisCOVID-19SARS-CoV-2DMTseroprevalence |
| spellingShingle | Agustín Sancho-Saldaña Anna Gil-Sánchez Cristina González-Mingot Silvia Peralta Maria Jose Solana Pascual Torres Alba Juanes Laura Quibus Emilio Ruiz Eduardo Sanpedro Bibiana Quirant-Sánchez Eva Martínez-Cáceres Cristina Ramo Tello Silvia Presas-Rodríguez Sebatián García Rubio Beatriz Pardiñas Baron Lluís Ramió-Torrentà Javier Sotoca Inés González-Suárez Sara Eichau José M. Prieto-González Maria Rosario Blasco Quilez Julia Sabín-Muñoz Antonio José Sánchez-López Gloria Llorens Calatayud Carmen Calles Ángel Pérez Sempere Moises Garcés Olga Carmona Ester Moral José Vicente Hervás Yolanda Blanco Nuria Sola-Valls Nieves Tellez Lara Lucía Forero Luis Brieva Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study Journal of Clinical Medicine Multiple Sclerosis COVID-19 SARS-CoV-2 DMT seroprevalence |
| title | Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_full | Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_fullStr | Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_full_unstemmed | Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_short | Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study |
| title_sort | seroprevalence of sars cov 2 in patients with multiple sclerosis under disease modifying therapies a multi centre study |
| topic | Multiple Sclerosis COVID-19 SARS-CoV-2 DMT seroprevalence |
| url | https://www.mdpi.com/2077-0383/12/23/7243 |
| work_keys_str_mv | AT agustinsanchosaldana seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT annagilsanchez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT cristinagonzalezmingot seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT silviaperalta seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT mariajosesolana seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT pascualtorres seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT albajuanes seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT lauraquibus seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT emilioruiz seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT eduardosanpedro seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT bibianaquirantsanchez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT evamartinezcaceres seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT cristinaramotello seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT silviapresasrodriguez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT sebatiangarciarubio seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT beatrizpardinasbaron seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT lluisramiotorrenta seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT javiersotoca seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT inesgonzalezsuarez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT saraeichau seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT josemprietogonzalez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT mariarosarioblascoquilez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT juliasabinmunoz seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT antoniojosesanchezlopez seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT gloriallorenscalatayud seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT carmencalles seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT angelperezsempere seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT moisesgarces seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT olgacarmona seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT estermoral seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT josevicentehervas seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT yolandablanco seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT nuriasolavalls seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT nievestellezlara seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT luciaforero seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy AT luisbrieva seroprevalenceofsarscov2inpatientswithmultiplesclerosisunderdiseasemodifyingtherapiesamulticentrestudy |